Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials

Autor: Bernt Johan von Scholten, Erik Christiansen, Matthias von Herrath, Two Investigators, Lars Bardtrum, Thomas F. Dejgaard, Sten Madsbad, Frederik Flindt Kreiner, Chantal Mathieu, One

Publikováno v: Diabetes Obes Metab
Dejgaard, T F, Scholten, B J V, Christiansen, E, Kreiner, F F, Bardtrum, L, Herrath, M V, Mathieu, C & Madsbad, S 2021, ' Efficacy and Safety of Liraglutide in Type 1 Diabetes by Baseline Characteristics in the ADJUNCT ONE and ADJUNCT TWO Randomized Clinical Trials ', Diabetes, Obesity and Metabolism, vol. 23, no. 12, pp. 2752-2762 . https://doi.org/10.1111/dom.14532

Aims Evaluate 26 weeks’ liraglutide treatment in type 1 diabetes (T1D) by subgroups in the ADJUNCT ONE and TWO trials. Materials and Methods ADJUNCT ONE and TWO were randomized controlled phase 3 trials in 1,398 and 835 participants with T1D treate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e73ed4c35a3647883eb62d7dca7e841c
https://lirias.kuleuven.be/handle/123456789/680609

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.